ClinicalTrials.gg

Program

LT-002-158

A development code. Also written as “LT-002-158 tablets” and “LT-002-158 Tablets”.

Its studies are mostly in Dermatitis, Atopic · Hidradenitis Suppurativa, led by Leadingtac Pharmaceutical (Shaoxing).

Furthest: phase 2, since Apr 2, 20253 company-led studies, 3 open or runningNext primary completion: Jan 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Leadingtac Pharmaceutical (Shaoxing)33 open or runningphase 2since Apr 2, 2025Apr 2, 2025Jan 2028phase 2 · NCT07895615

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 2, 2025First studies: 2 phase 2 studiesFirst studyNCT06932003, NCT06931990
  2. Oct 19, 2026Phase 2 study in Dermatitis, AtopicNCT07895615 · 160 planned · China

Ahead

  1. Jan 2028Primary completion: phase 2 study in Dermatitis, AtopicNCT07895615
  2. Feb 17, 2028Primary completion: phase 2 study in Dermatitis, AtopicNCT06931990
  3. Oct 30, 2028Primary completion: phase 2 study in Hidradenitis SuppurativaNCT06932003

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07895615Dermatitis, Atopic · China2RecruitingJan 2028160
NCT06932003Hidradenitis Suppurativa · China2RecruitingOct 30, 202812
NCT06931990Dermatitis, Atopic · China2RecruitingFeb 17, 202824

How it is read

Names in the registry

  • “LT-002-158”, 1 entry
  • “LT-002-158 tablets”, 1 entry
  • “LT-002-158 Tablets”, 1 entry

Codes read as this program: LT002158.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.